Felycin®-CA1 (sirolimus delayed-release tablets) Redefines Feline Cardiac Care
PENSACOLA, Fla., June 12, 2025 /PRNewswire/ -- Pegasus Laboratories/PRN Pharmacal has announced the addition of a new FDA conditionally approved drug, Felycin®-CA1 (sirolimus delayed-release tablets), to their portfolio. This first-in-class therapy is designed to manage ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM), representing a major milestone in feline medicine and offering new hope to owners of cats living with this progressive and often fatal disease.
HCM is a heart condition which causes the muscular walls of a cat's heart to become abnormally thick, reducing the heart's ability to pump blood efficiently. This can lead to heart failure and other complications, including sudden death. Many cats with HCM remain subclinical for years, while others may develop symptoms of congestive heart failure.
While the exact cause of the disease is not fully understood, HCM is more common in certain breeds, including British Shorthair, Chartreux, Maine Coon, Persian, Ragdoll, and Sphynx cats. Researchers have also identified mutations in various cardiac genes causing HCM in several of these breeds.
'Felycin-CA1 signals a turning point in feline medicine by providing veterinarians a much-needed option to help slow the progression of HCM beyond just managing the disease,' said Dr. Heather Davis, DVM, PhD, DACVS-LA, Director of Clinical Affairs and Veterinary Services at Pegasus Laboratories. 'It is a major step forward for cats and the people who care for them. For the first time, we're changing the conversation around what's possible in feline heart care.'
FDA conditional approval of Felycin®-CA1 follows results from a multi-center study demonstrating its ability to improve key cardiac outcomes, while also proving its ease of use in everyday veterinary practices.
'Veterinarians have long-needed options beyond palliative care when it comes to feline HCM,' said Dr. Joshua Stern, DVM, PhD, DACVIM. 'With Felycin-CA1, we can offer a therapy that has been shown in our initial clinical trial to stop progressive heart muscle thickening, slowing disease progression. We believe this management option marks the beginning of a new chapter where innovation in feline therapeutics becomes the rule, not the exception.'
Felycin®-CA1 is slated to be available beginning August 2025, in 0.4 mg, 1.2 mg, and 2.4 mg tablet strengths by prescription from a licensed veterinarian. Cats should be screened for pre-existing liver disease before starting the medication, and it should not be used in cats with pre-existing liver disease or diabetes mellitus.
About Pegasus Laboratories
Pegasus Laboratories, Inc., based in Pensacola Florida, is a pharmaceutical development and manufacturing organization focused on innovative products to treat chronic conditions in cats, dogs, and horses. Our products go to market under the PRN® Pharmacal brand. We also serve as a contract manufacturer for the Animal Health industry. We were founded in 1985 and acquired by PBI-Gordon Companies, Inc. in 1999.
View original content to download multimedia: https://www.prnewswire.com/news-releases/felycin-ca1-sirolimus-delayed-release-tablets-redefines-feline-cardiac-care-302479557.html
SOURCE Pegasus/PRN Pharmacal
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
4 hours ago
- Business Wire
LifeScan Reaches Milestone Transaction to Improve Financial Flexibility and Enable Future-Focused Investments
MALVERN, Pa.--(BUSINESS WIRE)--LifeScan, Inc. ('LifeScan' or the 'Company'), a world leader in blood glucose monitoring, today announced that it has entered into a Restructuring Support Agreement ('RSA') with its first- and second-lien lenders and current equity sponsor, Platinum Equity, that will transform its balance sheet and position the Company for a stronger and more profitable future. As contemplated in the RSA, LifeScan expects to reduce more than 75% of its debt, which will enable the Company to accelerate strategic investments that will support the future of the business. To implement the RSA as efficiently as possible, LifeScan filed voluntary petitions for prearranged chapter 11 cases in the United States Bankruptcy Court for the Southern District of Texas (the 'Court'). LifeScan's international subsidiaries are not included in the chapter 11 filing in the U.S. The Company expects to emerge from this process under the majority ownership of a group of the Company's existing lenders, with whom it has had a longstanding and productive relationship. Importantly, the Company's financial partners recognize the strong and growing potential of the glucose management industry, and through this process have committed their support for LifeScan's go-forward strategy. 'This balance sheet restructuring will significantly strengthen LifeScan's financial position, enabling us to continue serving more than 20 million customers across 50+ countries and put new growth strategies in place,' said Valerie Asbury, Chief Executive Officer of LifeScan. 'LifeScan is always evolving to meet the needs of our valued customers. In the U.S., we will continue to take action to expand access to OneTouch® so consumers can continue to manage their health with our reliable and affordable products, without the need for a prescription. We recognize that our products are essential for people with diabetes to make life-sustaining decisions and are evolving our model to bring products and services to market through multiple channels. I am deeply grateful for the partnership of our lenders and sponsor and the unyielding commitment of our employees, which will enable us to become a stronger company and create a world without limits for people with diabetes.' With a stronger financial foundation upon emerging from this process, LifeScan will be better positioned to invest in its global business. The Company will continue to prioritize product availability and superior customer service as it works proactively to become one of the most comprehensive players in the glucose management industry. As part of this effort, the Company intends to accelerate strategies in the U.S. market that offer both stronger economics and more predictable patient access. LifeScan will continue to operate in the ordinary course of business during its chapter 11 cases and is focused on delivering on its commitments to customers, vendors, and employees. The Company has filed a number of customary 'first day' motions which, upon approval by the Court, will enable LifeScan to continue operating as usual, including continuing to pay employee wages and benefits, maintaining customer programs, and honoring post-petition obligations to vendors. The Company expects to have the necessary liquidity to support operations during this process and anticipates emerging from chapter 11 by the end of the year. Additional information is available through the Company's claims agent, Epiq at Stakeholders with questions can contact Epiq by calling 888-832-9472 (U.S./Canada) or 971-318-6618 (International) or emailing lifescaninfo@ Advisors Milbank LLP and Porter Hedges LLP are serving as legal advisors, Alvarez & Marsal is serving as financial and restructuring advisor, PJT Partners LP is serving as investment banker, and C Street Advisory Group is serving as strategic communications advisor to the Company. Davis Polk & Wardwell LLP is serving as legal advisor and Houlihan Lokey is serving as investment banker to an ad hoc group of lenders that entered into the RSA. About LifeScan LifeScan is a global leader in blood glucose monitoring and digital health technology and has a vision to create a world without limits for people with diabetes. More than 20 million people and their caregivers around the world count on LifeScan's OneTouch® brand products to manage their diabetes. Together, LifeScan and OneTouch® improve the quality of life for people with diabetes with products and digital platforms defined by simplicity, accuracy, and trust. For more information, please visit
Washington Post
5 hours ago
- Washington Post
West Virginia's near-total abortion pill ban upheld by federal court
A divided federal appeals court on Tuesday allowed West Virginia to restrict access to mifepristone, the pill used to end pregnancies that has emerged as a focal point of legal battles over abortion. The decision marks the first time a federal appeals court has allowed a state to strictly limit the drug, teeing up a key test of states' powers to ban medication approved by the Food and Drug Administration.
The Hill
6 hours ago
- The Hill
Appeals court upholds West Virginia's medication abortion ban
A divided federal appeals court panel on Tuesday upheld West Virginia's ban on medication abortion, ruling that the law does not conflict with the Food and Drug Administration's ability to regulate the drug. The U.S. Court of Appeals for the Fourth Circuit dismissed mifepristone manufacturer GenBioPro's effort to strike down West Virginia's near-total abortion ban in a 2-1 decision. The court ruled FDA's approval of mifepristone did not preempt West Virginia's law. GenBioPro produces a majority of the mifepristone sold in the United States, and has held FDA approval for generic mifepristone since 2019. GenBioPro argued that FDA's authority to impose regulations on the prescription and distribution of mifepristone superseded state efforts to restrict access to medications. A lower court ruled against the company, which then appealed the decision. Circuit Judge J. Harvie Wilkinson wrote that a 2007 federal law 'leaves the states free to adopt or diverge from West Virginia's path' and it 'falls well short of expressing a clear intention to displace the states' historic and sovereign right to protect the health and safety of their citizens.' The ruling is the first time a federal appeals court has said states can restrict use of mifepristone. Twenty-eight states restrict access to medication abortions, according to the reproductive health nonprofit Guttmacher Institute. The Supreme Court upheld access to mifepristone last year, when it unanimously dismissed a lawsuit seeking to roll back changes FDA made in 2016 and 2021 to expand access. 'We respect the fact that appellant and some amici have argued that access to mifepristone is important to the health of women in the course of their reproductive choices,' Wilkinson wrote. 'Our objection is not to the substance of this point, but to the venue in which it is advanced.' Wilkinson was appointed by President Reagan. He was joined by U.S. District Judge Rossie Alston, an appointee of President Trump. 'The court is allowing the state to continue putting those seeking medication abortion care in harm's way,' GenBioPro CEO Evan Masingill said in a statement. 'The panel's ruling allows states to restrict access to medications that FDA has deemed safe and effective, threatening a dangerous ripple effect on the availability of essential medications in this country. As we have always made clear, GenBioPro will not stop fighting to ensure all people can access safe, evidence-based healthcare.' West Virginia Gov. Patrick Morrisey (R) said in a statement he was 'proud to see a victory in this case.' 'West Virginia can continue to enforce our pro-life laws and lead the nation in our efforts to protect life. We will always be a pro-life state!' he said. In a dissent, Circuit Judge DeAndrea Gist Benjamin said the state's law 'erects barriers to life-saving healthcare for countless West Virginians in ways not envisioned by Congress.' Benjamin, who was appointed by former President Biden, added that 'the twin sensitivities of abortion access and states' rights cannot influence our willingness to recognize the Food and Drug Administration's (FDA) clear authority in this area.' 'By criminalizing medical providers and prohibiting medication abortions, then, West Virginia has exceeded the ability to regulate abortion as established in Dobbs and has trespassed on the FDA's authority to regulate the safe use of and unburdened access to mifepristone,' Benjamin wrote.
